Skip to content

The Research Briefing

The studies behind the conversation.

Clinical trials help show what happened for a defined group of participants under defined study conditions. They are an important part of the picture—not a prediction of any one person’s result.

Look at the result. Then look at who was studied, what was compared, and what remains unanswered.

Reading the Evidence

Five things to look for in every study.

  • 01 ·Who Was Studied

    Eligibility criteria determine who the findings most directly apply to.

  • 02 ·What Was Compared

    A meaningful trial states the medicine, dose, comparator, and accompanying care.

  • 03 ·How Long It Lasted

    Timeframe matters when interpreting benefits, risks, maintenance, and discontinuation.

  • 04 ·What Was Measured

    Weight, cardiovascular events, quality of life, safety, and other outcomes answer different questions.

  • 05 ·What It Does Not Answer

    No single trial can settle every question about long-term use or every person’s experience.

Study 01 · Randomized Controlled Trial

Semaglutide in STEP 1

Who Was Studied
1,961 adults with overweight or obesity and no diabetes.[1]
What Was Compared
Once-weekly semaglutide 2.4 mg plus lifestyle intervention versus placebo plus lifestyle intervention for 68 weeks.[1]
What Happened
Mean body-weight change was −14.9% with semaglutide versus −2.4% with placebo. Nausea and diarrhea were the most common adverse events; gastrointestinal events led to discontinuation in 4.5% of semaglutide participants and 0.8% of placebo participants.[1]
What This Does Not Answer
It does not predict every individual outcome or settle longer-term outcomes beyond the trial period.

Study 02 · Randomized Controlled Trial

Tirzepatide in SURMOUNT-1

Who Was Studied
2,539 adults with obesity, or overweight plus at least one weight-related complication, excluding diabetes.[2]
What Was Compared
Once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks, with lifestyle intervention.[2]
What Happened
Mean body-weight change was −15.0%, −19.5%, and −20.9% across the 5 mg, 10 mg, and 15 mg groups, respectively, versus −3.1% with placebo. The most common adverse events were gastrointestinal and largely mild to moderate, mainly during dose escalation.[2]
What This Does Not Answer
It does not establish a single expected result for every person or make different treatment options interchangeable.

Study 03 · Cardiovascular Outcomes Trial

Semaglutide in SELECT

Who Was Studied
17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, but no diabetes.[3]
What Was Compared
Once-weekly semaglutide 2.4 mg versus placebo. Mean follow-up was 39.8 months.[3]
What Happened
A primary cardiovascular event—death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke—occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.[3]
What This Does Not Answer
The result applies to the specific studied population and should not be generalized to every person considering GLP-1 treatment.

Study 04 · Maintenance / Withdrawal Trial

What STEP 4 can tell us about continuing or stopping semaglutide

The question “What happens when you stop?” is one of the most important conversations in this space. This study is useful context, not a universal answer.

Who Was Studied
803 adults with overweight or obesity who completed a 20-week semaglutide run-in and were then randomized.[4]
What Was Compared
Continuing semaglutide versus switching to placebo for 48 additional weeks, while lifestyle intervention continued.[4]
What Happened
From week 20 to week 68, estimated mean body-weight change was −7.9% among participants who continued semaglutide and +6.9% among participants switched to placebo.[4]
What This Does Not Answer
It does not show that every person will have the same experience after a treatment change. Individual decisions and support needs belong with a qualified healthcare professional.

Study 05 · Randomized Phase 3 Trials

Retatrutide and obstructive sleep apnea

Published October 2026 · New England Journal of Medicine

Who Was Studied
Adults with moderate-to-severe obstructive sleep apnea and a body-mass index of at least 27. The two trials included 243 participants without type 2 diabetes and 448 participants with type 2 diabetes.[9]
What Was Compared
Once-weekly investigational retatrutide at study doses of 4, 9, or 12 mg versus placebo over 80 weeks. These sleep-apnea studies were nested within the larger TRIUMPH-1 and TRIUMPH-2 trial programs.[9]
What Was Measured
The primary endpoint was change in the apnea–hypopnea index at 80 weeks for the 9 mg and 12 mg groups. This index measures the average number of breathing pauses and episodes of reduced breathing per hour of sleep.[9]
What Happened
Retatrutide produced significantly greater reductions in the apnea–hypopnea index than placebo in both trials. Body weight also decreased. Gastrointestinal adverse events were the most common adverse events.[9]
Why It Matters
The study examines a health outcome beyond body weight: sleep-apnea severity in a defined population. It provides context for conversations about the broader effects being investigated with incretin-based medicines.
What This Does Not Answer
It does not establish that every person with sleep apnea will respond similarly, that retatrutide should replace an individual’s existing care, or that other peptide products share its effects. The findings concern the investigational medicine and populations studied, not a general endorsement of peptide treatments.
Study Context
The trials were funded by Eli Lilly. The primary sleep-apnea analysis used a prespecified hybrid approach to handle certain events occurring during treatment; intention-to-treat results were also reported. These are analyses within larger trial programs, not entirely separate populations from all other TRIUMPH publications.[9]

Individual treatment decisions belong with a qualified healthcare professional.

Beyond the Trial

Why guidance, quality, and context matter.

  • WHO Guidance

    In 2025, WHO issued conditional recommendations for GLP-1 therapies in adult obesity as part of comprehensive care, noting ongoing questions around long-term evidence, maintenance, discontinuation, cost, and equity.[5]

  • FDA Product-Safety Information

    FDA says unapproved versions of semaglutide and tirzepatide do not undergo FDA review for safety, effectiveness, or quality before marketing. Approval status, sourcing, and dosing matter.[6]

  • Lifestyle Context

    Public guidance from Harvard T.H. Chan School of Public Health discusses nutrition, hydration, protein, aerobic activity, and strength training as considerations alongside GLP-1 treatment. This is information—not an event endorsement or clinical protocol.[7]

Keep the Context

Evidence informs the conversation. It does not replace care.

Clinical trials do not replace an individual conversation with a qualified healthcare professional. They also do not replace nutrition support, attention to strength and energy, discussion of cost and access, or the lived experience of navigating change over time.

This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.

Research is only useful if it leads to better questions.

Explore the conversations, or contribute a question the Research Briefing should help examine.

Sources & References

  1. [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa2032183 (opens in a new tab)
  2. [2]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa2206038 (opens in a new tab)
  3. [3]Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa2307563 (opens in a new tab)
  4. [4]Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical TrialJAMAhttps://jamanetwork.com/journals/jama/fullarticle/2777886 (opens in a new tab)
  5. [5]WHO issues global guideline on the use of GLP-1 medicines in treating obesityWorld Health Organizationhttps://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity (opens in a new tab)
  6. [6]FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food & Drug Administrationhttps://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (opens in a new tab)
  7. [7]Diet, exercise still important when taking weight-loss medicationHarvard T.H. Chan School of Public Healthhttps://hsph.harvard.edu/news/diet-exercise-still-important-when-taking-weight-loss-medication/ (opens in a new tab)
  8. [8]Pros and cons of GLP-1 agonists for weight lossMayo Clinic Community Healthhttps://communityhealth.mayoclinic.org/featured-stories/weight-loss-drugs (opens in a new tab)
  9. [9]Retatrutide Once Weekly for Treatment of Obstructive Sleep ApneaNew England Journal of Medicine · Published October 2026https://www.nejm.org/doi/full/10.1056/NEJMoa2611477 (opens in a new tab)